Werewolf Therapeutics SEC filings document material events, operating results, governance matters, and capital-structure disclosures for a Delaware biopharmaceutical company developing conditionally activated immune therapeutics. Recent 8-K filings furnish quarterly financial results, press-release exhibits, and updates tied to the company’s PREDATOR, INDUKINE, and INDUCER programs.
The filings also cover Nasdaq continued-listing matters, audit committee composition, exit and disposal activities, emerging growth company status, common stock registered under the HOWL symbol, shareholder voting matters, clinical and regulatory disclosures, and risk language related to strategy, operations, development plans, and corporate alternatives.
Werewolf Therapeutics, Inc. is a clinical-stage biotech developing conditionally activated cytokine therapies and T‑cell engagers for cancer and immune diseases using its PREDATOR platform. The company discloses substantial doubt about its ability to continue as a going concern and is exploring strategic alternatives, including a possible sale or merger.
In February 2026 it adopted a restructuring plan, reducing its workforce by 64% and expecting about $4.1 million of severance and related charges in the first quarter of 2026. Lead IL‑2 INDUKINE candidate WTX‑124 showed a 21% objective response rate as monotherapy in heavily pretreated metastatic melanoma and 30% in patients who were not primary resistant to immunotherapy, with an FDA‑accepted 18 mg recommended dose and initial monotherapy registration guidance in post‑ICI melanoma. IL‑12 INDUKINE WTX‑330 produced a confirmed partial response in metastatic gall bladder cancer with a 45% tumor reduction and favorable pharmacokinetics. Further advancement of all programs depends on additional funding and outcomes of the strategic review.
Werewolf Therapeutics reported fourth quarter and full-year 2025 results and launched a formal review of strategic alternatives that could include a sale, merger, asset sale, licensing deals or other transactions. The company hired Piper Sandler as exclusive financial advisor and emphasized there is no set timeline or assurance any deal will occur.
For the quarter ended December 31, 2025, net loss narrowed to $8.4M from $20.4M a year earlier, driven by lower research and development expenses of $6.9M versus $15.7M, and general and administrative expenses of $2.5M versus $4.6M. Full-year 2025 net loss improved to $60.8M from $70.5M, with R&D at $44.8M and G&A at $15.8M.
As of December 31, 2025, cash and cash equivalents were $57.1M, down from $111.0M a year earlier. The company expects this cash to fund operations into the fourth quarter of 2026, while it continues advancing its INDUKINE and INDUCER immune-oncology platforms and clinical candidates WTX-124 and WTX-330.
Werewolf Therapeutics, Inc. VP of Finance & Corporate Controller Michael J. Urban filed an initial Form 3 showing his equity holdings. He directly holds stock options covering 52,500 shares at an exercise price of $3.6500, 29,365 shares at $4.6400, 10,000 shares at $1.5700, and 54,800 shares at $1.5600, with expiration dates ranging from 2033 to 2035. He also directly owns 5,284 shares of Werewolf Therapeutics common stock.
Werewolf Therapeutics, Inc. announced that its board has initiated a process to explore a full range of strategic alternatives to advance its drug development platform and pipeline and to maximize stockholder value. The company has engaged Piper Sandler & Co. as its exclusive financial advisor for this evaluation.
Potential options under consideration include a sale of the company, a business combination or merger, a sale of assets, licensing or collaboration arrangements, or other strategic transactions. Werewolf stated it has no defined timeline for this review and there is no assurance that the process will result in any transaction or agreement, and it does not intend to provide further updates unless a specific action is approved or additional disclosure is deemed appropriate.
Werewolf Therapeutics, Inc. approved a major restructuring that will cut 64% of its workforce, with the reduction expected to be largely complete by February 13, 2026. The company plans to record an estimated $4.1 million one-time charge in the first quarter of 2026 for severance and related cash benefits.
As part of this action, Chief Financial Officer Timothy W. Trost and Chief Medical Officer Dr. Randi Isaacs will resign their roles effective February 13, 2026, each receiving severance equal to nine months of base salary plus nine months of company-paid COBRA contributions and extended stock option exercise periods. Both will continue under consulting agreements at $250 per hour for up to six months. The company appointed Michael Urban, previously Vice President of Finance and Corporate Controller, as principal financial and accounting officer effective February 13, 2026.
The company also disclosed that in late 2025 and early 2026 it sought to raise capital and is now evaluating alternatives to maximize stockholder value, including strategic partnerships for its WTX-124 and WTX-330 INDUKINE programs, with no assurance any transaction will occur.